RECRUITING

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate a new diagnostic imaging test, positron emission tomography (PET), with a different radioactive form of iodine called iodine-124. This form is able to accurately measure the amount of radioactive iodine uptake in the cancer. If the new test determines sufficient radioiodine uptake in the cancer, treatment will continue as usual. However, if the new test shows only low radioiodine uptake, a decision may be made that the benefit from radioiodine therapy is insufficient and that another form of therapy is preferred.

Official Title

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

Quick Facts

Study Start:2018-08-21
Study Completion:2026-08
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03647358

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adults with thyroid carcinoma confirmed by pathology.
  2. * Adult thyroid carcinoma patients who have undergone total thyroidectomy
  3. * Adult thyroid carcinoma patients have metastatic disease or suspicion for metastatic disease, or are under a protocol intended to explore re-induction therapy for 131I uptake, and are about to undergo Thyrogen-assisted dosimetry, unless Thyrogen-assisted dosimetry is not required per standard of care.
  4. * The patient and physician are planning to administer 131I for therapy if persistent radioiodine-avid metastases are present.
  5. * All subjects must have measurable disease, documented within the previous six months by ultrasonography (US), MRI, FDG PET/CT, or CT scanning.
  1. * Age less than 18 years.
  2. * Patients who are pregnant.

Contacts and Locations

Study Contact

Ravinder Grewal, MD
CONTACT
212-639-2872
grewalr@mskcc.org
Steven Larson, MD
CONTACT
646-888-2212

Principal Investigator

Ravinder Grewal, MD
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States
Weill Cornell Medical Center
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Ravinder Grewal, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-08-21
Study Completion Date2026-08

Study Record Updates

Study Start Date2018-08-21
Study Completion Date2026-08

Terms related to this study

Keywords Provided by Researchers

  • Iodine-124
  • PET Scan
  • 18-253

Additional Relevant MeSH Terms

  • Thyroid Carcinoma
  • Metastatic Thyroid Carcinoma